1. G4 patent application pending in China.
2&3. Based on self-reported participant feedback from a 28-day product trial (n=33). Individual results may vary.
4. G4 Patent application pending in China.
5. Based on in-vitro laboratory testing of G4.
Ingredient information is based on;ingredient-level research and specifications and does not represent clinical outcomes of the finished product. Based on self-reported participant feedback from a 28-day product trial (n=33). Individual results may vary.
6. based on in-vitro strain testing; 73% refers to α-glucosidase activity under laboratory conditions. Not a human clinical outcome; no effect on carbohydrate absorption or blood glucose is implied.
7. published in-vitro study; 57.9% refers to AGE formation inhibition in a BSA–fructose model.
8. published in-vitro study; 75.2% refers to CML formation inhibition in a BSA–glucose model. CML is an advanced glycation end-product.
9. Enzogenol® + vitamin C: published human study, n=24; 51% refers to plasma protein carbonyls after 6 weeks. Study doses and conditions differ from AGE DEFENSE.